An update for Richter syndrome - new directions and developments (Q38691261)

5 September 2017

An update for Richter syndrome - new directions and developments (English)

1 reference

5 September 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28439883%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Anna Schuh

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28439883%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

language of work or name

English

0 references

publication date

25 April 2017

1 reference

British Journal of Haematology

5 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28439883%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

178

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28439883%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

508-520

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28439883%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28439883%20AND%20SRC:MED&resulttype=core&format=json

NOTCH1 mutations in CLL associated with trisomy 12.

7 June 2020

cites work

1 reference

Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma

21 January 2018

1 reference

Hematopoietic stem cells: to be or Notch to be.

21 January 2018

1 reference

Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature

21 January 2018

1 reference

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.

21 January 2018

1 reference

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

21 January 2018

1 reference

Hematopoietic stem cell fate is established by the Notch-Runx pathway

21 January 2018

1 reference

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

21 January 2018

1 reference

Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far.

21 January 2018

1 reference

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

21 January 2018

1 reference

Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome.

21 January 2018

1 reference

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy

21 January 2018

1 reference

Large-cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine-rituximab-containing regimens: natural history- or therapy-related complication?

21 January 2018

1 reference

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma wor

21 January 2018

1 reference

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome

21 January 2018

1 reference

NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL

21 January 2018

1 reference

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

21 January 2018

1 reference

Immune checkpoint inhibition in lymphoid disease.

21 January 2018

1 reference

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome

21 January 2018

1 reference

Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia

21 January 2018

1 reference

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

21 January 2018

1 reference

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial

21 January 2018

1 reference

Ibrutinib and rituximab induced rapid response in refractory Richter syndrome

21 January 2018

1 reference

Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation

21 January 2018

1 reference

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

21 January 2018

1 reference

Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.

21 January 2018

1 reference

Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease.

21 January 2018

1 reference

Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers

21 January 2018

1 reference

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study

21 January 2018

1 reference

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

21 January 2018

1 reference

2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation.

21 January 2018

1 reference

Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients

21 January 2018

1 reference

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).

21 January 2018

1 reference

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

21 January 2018

1 reference

Richter syndrome: molecular insights and clinical perspectives

21 January 2018

1 reference

Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome

21 January 2018

1 reference

The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation.

21 January 2018

1 reference

Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia

21 January 2018

1 reference

Diagnostic dilemmas of high-grade transformation (Richter's syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP-OR clinical trial specialist haemato-pathology central review

21 January 2018

1 reference

The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011).

21 January 2018

1 reference

A phase II study of RO4929097 in metastatic colorectal cancer

21 January 2018

1 reference

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

21 January 2018

1 reference

Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis

21 January 2018

1 reference

Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors

21 January 2018

1 reference

The efficacy of ibrutinib in the treatment of Richter syndrome

21 January 2018

1 reference

Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders

21 January 2018

1 reference

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients wit

21 January 2018

1 reference

Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation

21 January 2018

1 reference

Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience.

21 January 2018

1 reference

Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome

21 January 2018

1 reference

NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome.

21 January 2018

1 reference

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial

21 January 2018

1 reference

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study

21 January 2018

1 reference

Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

21 January 2018

1 reference

TP53 mutation and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.14700

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28439883%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

1 reference